Drug maker Pharmstandard said Thursday its third-quarter sales soared 84 percent, year-on-year, boosted by an early state tender for anti-cancer drugs.
Sales totaled 14.7 billion rubles, versus 8 billion rubles in the same period last year, the company said in a statement.
It said sales of Johnson & Johnson's anti-cancer drug Velcade totaled 4.8 billion rubles, accounting for one-third of total revenue, after the government shifted its tender to the third quarter from the fourth quarter.
As a result, total sales of third-party products soared 308 percent to stand at 8.1 billion rubles, while sales of the company's own drugs were up 8.3 percent to 6.2 billion rubles.
(Reuters)
Related articles:
